# Pathology Full-Module R2 — Gold Rubric Evidence

Date: 2026-07-12
Scope: all 12 numbered guides in `pathology/`
Reviewer lenses: Gold Rubric v2, reference-editor, expert-skeptic, mechanical proof
Decision: **Silver for every guide; no Certified Gold registry insertion**

Final sign-off: **PASS — Pulse 05 DONE (2026-07-12); no unresolved BLOCK/WARN**

## Claim Boundary and Mechanical Record

This is a guide-specific review, not a cohort score copied across the module. Every
guide meets the content-side Gold threshold used here: average at least 4.5, no
dimension below 4, at least three reader tasks pass, and no unresolved adversarial
BLOCK/WARN remains. That does **not** establish Certified Gold.

- **Ordinary focused PROOF:** PASS — `12 files checked, 0 errors, 0 warnings`.
- **Adversarial review:** prototype R1/R2, both scaling gates, and full-module R1
  complete; all findings repaired.
- **Da Vinci:** no pathology-specific invariant exists in `proof.toml`; ordinary
  PROOF cleanliness must not be represented as Da Vinci coverage.
- **Source custody:** `partial` for all twelve. PROOF literal backfill is recorded
  for 12/12; Git provenance is recorded for 0/12 and pending for 12/12 because the
  guides are untracked; authentic external/primary-source custody remains incomplete.
- **Registry:** no row is added to `context/gold/REGISTRY.md`, Certified Gold, or
  Candidate-Hardened.

The strongest honest tier is **Silver**: the guides are editorially strong,
adversarially repaired, and ordinary-PROOF-clean, but lack pathology-specific Da
Vinci protection and complete source custody. Those gaps are future promotion work,
not Pulse-05 blockers under the wave exit gate.

---

## `pathology/00-OVERVIEW.md`

| Gold dimension | Score | Guide-specific evidence |
|---|---:|---|
| Landscape power | 5 | The injury→lesion→specimen/result→diagnostic-pattern→signed-report chain places all eleven downstream guides on one causal spine. |
| Layering integrity | 5 | The two discipline axes, ownership table, four-pillar contract, guide map, recurring mechanism shape, navigation case, and routing tasks unpack the opening chain in order. |
| ASCII precision | 4 | The causal chain and discipline-axis diagrams are legible and semantically useful, though intentionally label-dense. |
| Explanatory compression | 4 | It compresses anatomic/clinical and general/systemic pathology without erasing the orthogonality of the two splits. |
| Decision utility | 5 | The boundary table and cheat sheet route mechanism, substrate, result, diagnosis, catalog, and clinical-decision questions to the correct owner. |
| Confusion handling | 5 | It directly rejects pathology-as-disease-catalog, laboratory-result interpretation as clinical action, and technique as an SOP. |
| Bridge quality | 5 | The compiler/pipeline and interface-contract bridges map the module without making software prior art load-bearing. |
| Cross-reference value | 5 | Exact guide and sibling links explain why the reader should leave the module, not merely where another file exists. |
| Voice | 5 | Peer-level, third-person, explicitly educational; the four-pillar boundary is operational rather than boilerplate. |
| Factual confidence | 4 | The discipline map and framework boundaries are well qualified; external claim custody remains partial. |

**Average: 4.7/5.**

| Reader task | Pass/fail evidence |
|---|---|
| Route a scar question between mechanism and substrate technique. | **PASS** — the worked navigation case sends “why it scarred” to `02` and “how the slide was made” to `09`. |
| Reconcile a laboratory-result/slide discordance without collapsing guide ownership. | **PASS** — solved Task 2 routes result generation to `08`, substrate to `09`, and diagnostic reconciliation/reporting to `10`. |
| Distinguish local result error from cross-process quality-system error. | **PASS** — solved Task 4 states the `08` per-result vs `11` program-level split. |

**Adversarial status:** R1 `RE-01` (missing navigation case/tasks) repaired; the
guide-05 malignancy wording propagated to the overview cheat sheet; no finding open.
**Ordinary PROOF:** PASS, 0 errors / 0 warnings.
**Da Vinci:** missing; no overview-specific pathology invariant.
**Source custody:** partial; PROOF backfill present, Git provenance pending, external
sources incomplete.
**Tier: Silver.**

---

## `pathology/01-CELL-INJURY-ADAPTATION-AND-DEATH.md`

| Gold dimension | Score | Guide-specific evidence |
|---|---:|---|
| Landscape power | 5 | The cell-stress state machine makes adaptation, reversible injury, irreversible injury, and death modes one navigable model. |
| Layering integrity | 5 | Injury targets, adaptation, reversible injury, commitment to death, necrosis, apoptosis, accumulations, calcification, and aging follow the state transitions. |
| ASCII precision | 4 | The state machine and intrinsic/extrinsic apoptosis diagrams are clear; the molecular labels are dense but controlled. |
| Explanatory compression | 5 | “Stress budget,” hysteresis, and point-of-no-return language compress cellular pathology without reducing it to alive/dead. |
| Decision utility | 5 | The guide selects adaptation vs injury, reversible vs irreversible state, necrosis pattern, and calcification mechanism from observations. |
| Confusion handling | 5 | It separates hypoxia from ischemia, adaptation from neoplasia, regulated necrosis from tidy death, and dystrophic from metastatic calcification. |
| Bridge quality | 5 | Graceful degradation, circuit breaking, and state-machine bridges illuminate rather than replace the biology. |
| Cross-reference value | 4 | The handoffs to `02`, `05`, `08`, `medicine/10`, genomics, and biochemistry are accurate but necessarily concise. |
| Voice | 5 | Third-person and mechanism-centered; no personal-result interpretation. |
| Factual confidence | 4 | Apoptosis is now correctly qualified as usually immunologically quiet with efficient clearance, with failed-clearance and immunogenic exceptions explicit; primary-source custody remains partial. |

**Average: 4.7/5.**

| Reader task | Pass/fail evidence |
|---|---|
| Explain ischemia-reperfusion injury. | **PASS** — Task 1 traces mitochondrial ROS, calcium overload, and recruited inflammatory injury. |
| Distinguish protective metaplasia from long-term transformation risk. | **PASS** — Task 2 explains the reversible adaptation and its dysplasia/neoplasia risk. |
| Explain what a tissue-specific death marker actually marks. | **PASS** — Task 5 links marker release to membrane-disruptive irreversible injury and qualifies promptly cleared apoptosis vs secondary membrane breakdown. |

**Adversarial status:** no R1 BLOCK/WARN specific to guide 01; final hygiene review
qualified apoptosis across diagrams, cases, tasks, cheat sheet, and confusions.
**Ordinary PROOF:** PASS, 0 / 0.
**Da Vinci:** missing; no state-machine or apoptosis-pathway invariant.
**Source custody:** partial; PROOF backfill present, Git provenance pending, external
sources incomplete.
**Tier: Silver.**

---

## `pathology/02-INFLAMMATION-AND-TISSUE-REPAIR.md`

| Gold dimension | Score | Guide-specific evidence |
|---|---:|---|
| Landscape power | 5 | The defense-program-with-repair-back-end diagram unifies acute inflammation, resolution, chronicity, regeneration, scar, and fibrosis. |
| Layering integrity | 5 | Vascular/cellular events lead to mediators, outcome forks, chronic inflammation, granulomas, repair, wound healing, and fibrosis. |
| ASCII precision | 4 | Program and fork diagrams preserve causality; mediator density limits visual sparseness. |
| Explanatory compression | 5 | The guide treats inflammation as a coordinated program and fibrosis as repair overshoot rather than disconnected fact lists. |
| Decision utility | 5 | It supports choosing acute vs chronic pattern, resolution vs regeneration vs scar, and granulomatous-pattern implications. |
| Confusion handling | 5 | Protective-vs-damaging inflammation, chronic inflammation vs chronic infection, granuloma vs diagnosis, and regeneration vs scar are explicit. |
| Bridge quality | 5 | Signaling fabric, orchestration, and repair-control-loop bridges are universal and technically apt. |
| Cross-reference value | 4 | Links to cell injury, immunopathology, hemodynamics, disease entities, and laboratory markers are useful but compact. |
| Voice | 5 | Mechanism-first, third-person, and non-advisory. |
| Factual confidence | 4 | Mediator and wound-healing claims are bounded and resource caveats are present; source custody is still partial. |

**Average: 4.7/5.**

| Reader task | Pass/fail evidence |
|---|---|
| Explain how inflammation can be protective and injurious. | **PASS** — Task 1 separates defense purpose from collateral tissue damage and persistence. |
| Predict regeneration vs scar. | **PASS** — Task 2 uses cell proliferative capacity, extracellular-matrix integrity, injury extent, and persistence. |
| Explain what “granulomatous inflammation” contributes without naming an entity. | **PASS** — Task 4 treats it as a mechanism-pattern that narrows cause classes and hands entity diagnosis to `disease/`. |

**Adversarial status:** no unresolved guide-specific R1 finding.
**Ordinary PROOF:** PASS, 0 / 0.
**Da Vinci:** missing; no inflammation/repair-fork invariant.
**Source custody:** partial; PROOF backfill present, Git provenance pending, external
sources incomplete.
**Tier: Silver.**

---

## `pathology/03-HEMODYNAMIC-DISORDERS-THROMBOSIS-AND-SHOCK.md`

| Gold dimension | Score | Guide-specific evidence |
|---|---:|---|
| Landscape power | 5 | The circulation model combines pressure, flow, volume, endothelial integrity, hemostasis, thrombosis, embolism, infarction, and shock. |
| Layering integrity | 5 | Fluid balance and congestion lead into normal hemostasis, pathological thrombosis, thrombus fate, embolism, infarction, and systemic collapse. |
| ASCII precision | 4 | Flow/pressure and cascade diagrams are clear, though the hemostasis/thrombosis labels are necessarily compact. |
| Explanatory compression | 5 | Virchow's triad and shock as a final common pathway compress a broad field into reusable causal structures. |
| Decision utility | 5 | The guide differentiates edema mechanisms, thrombus drivers, embolic routing, infarct morphology, and shock classes. |
| Confusion handling | 5 | Hyperemia vs congestion, thrombus vs clot, embolus vs thrombus, red vs white infarct, and bleeding-plus-clotting are directly handled. |
| Bridge quality | 5 | Network flow, backpressure, self-sealing repair, and cascading-failure bridges fit the mechanisms. |
| Cross-reference value | 4 | The guide connects injury, inflammation, laboratory testing, and disease entities without duplicating them. |
| Voice | 5 | Third-person and explanatory; no acute-care instruction. |
| Factual confidence | 4 | The cascade is mechanistically sound and caveated; external source custody remains partial. |

**Average: 4.7/5.**

| Reader task | Pass/fail evidence |
|---|---|
| Explain why hemostasis can save or kill. | **PASS** — Task 1 contrasts localized regulated sealing with inappropriate or propagated thrombosis. |
| Predict where an embolus lodges. | **PASS** — Task 2 follows source, flow path, vessel caliber, and shunts. |
| Distinguish warm distributive shock from vasoconstricted shock. | **PASS** — Task 4 explains vascular tone, effective circulating volume, and compensatory state. |

**Adversarial status:** no unresolved guide-specific R1 finding.
**Ordinary PROOF:** PASS, 0 / 0.
**Da Vinci:** missing; no circulation-failure invariant.
**Source custody:** partial; PROOF backfill present, Git provenance pending, external
sources incomplete.
**Tier: Silver.**

---

## `pathology/04-IMMUNOPATHOLOGY-AND-TISSUE-INJURY.md`

| Gold dimension | Score | Guide-specific evidence |
|---|---:|---|
| Landscape power | 5 | The friendly-fire map organizes hypersensitivity, autoimmunity, transplant injury, immunodeficiency lesions, and amyloid deposition by injury mechanism. |
| Layering integrity | 5 | The four hypersensitivity mechanisms establish the vocabulary used by the later autoimmunity and transplant sections. |
| ASCII precision | 4 | Effector-to-lesion diagrams are readable; immune nomenclature creates unavoidable density. |
| Explanatory compression | 5 | The guide classifies immune injury by mechanism rather than disease name and keeps immune-cell biology deferred. |
| Decision utility | 5 | It distinguishes types I–IV, rejection time courses, immunodeficiency lesion patterns, and amyloid as a family of deposits. |
| Confusion handling | 5 | Type II vs III, autoimmunity vs hypersensitivity, graft rejection vs GVHD, and missing immunity vs resulting lesion are explicit. |
| Bridge quality | 4 | Friendly-fire and authorization/revocation bridges are useful, though less structurally pervasive than in the strongest guides. |
| Cross-reference value | 5 | Defers immune-cell mechanics to `immunology/` while linking tissue consequences to inflammation, genetics, and disease entities. |
| Voice | 5 | Peer-level, third-person, and mechanism-centered. |
| Factual confidence | 4 | Gell-Coombs and transplant categories are appropriately framed; source custody remains partial. |

**Average: 4.7/5.**

| Reader task | Pass/fail evidence |
|---|---|
| Distinguish type II from type III injury. | **PASS** — Task 2 separates fixed cell/matrix targets from circulating immune-complex deposition. |
| Explain rejection timing as mechanism. | **PASS** — Task 3 connects hyperacute, acute, and chronic patterns to preformed antibody, cellular/antibody injury, and remodeling. |
| Explain why infection can be the pathology of immunodeficiency. | **PASS** — Task 4 distinguishes the missing defense component from the tissue lesion it permits. |

**Adversarial status:** no unresolved guide-specific R1 finding.
**Ordinary PROOF:** PASS, 0 / 0.
**Da Vinci:** missing; no hypersensitivity-mechanism invariant.
**Source custody:** partial; PROOF backfill present, Git provenance pending, external
sources incomplete.
**Tier: Silver.**

---

## `pathology/05-NEOPLASIA-CARCINOGENESIS-AND-TUMOR-BIOLOGY.md`

| Gold dimension | Score | Guide-specific evidence |
|---|---:|---|
| Landscape power | 5 | The escaped-control clone diagram connects autonomy, clonality, hallmarks, carcinogenesis, invasion, metastasis, grade, stage, and microenvironment. |
| Layering integrity | 5 | Definition and differentiation precede nomenclature, capabilities, acquisition, invasion/spread, classification, and immunity. |
| ASCII precision | 4 | Control-loss and invasion-cascade figures are clear; the hallmark set is label-heavy. |
| Explanatory compression | 5 | The clone/control model and acquired-capabilities framing compress tumor biology without becoming a tumor catalog. |
| Decision utility | 5 | It separates benign from malignant behavior, grade from stage, epithelial in-situ/invasive criteria, and marker use from diagnosis. |
| Confusion handling | 5 | The repaired text explicitly prevents basement-membrane invasion from becoming a universal malignancy definition and distinguishes hematologic disease. |
| Bridge quality | 5 | Control-plane escape, selection, capability acquisition, and ecosystem bridges are coherent. |
| Cross-reference value | 4 | Strong handoffs to `10`, genomics, immunology, and `disease/`; entity specifics are intentionally deferred. |
| Voice | 5 | Third-person and non-diagnostic for the reader. |
| Factual confidence | 4 | R1 repaired the major epithelial-vs-general malignancy overclaim; hallmarks and classification systems remain dated/qualified with partial custody. |

**Average: 4.7/5.**

| Reader task | Pass/fail evidence |
|---|---|
| Explain why growth rate alone does not define malignancy. | **PASS** — Task 1 uses destructive invasion/aggressive spread and differentiation rather than size or speed alone. |
| Separate grade from stage. | **PASS** — Task 2 distinguishes microscopic biological appearance from anatomical extent. |
| Explain why a tumor marker cannot diagnose cancer alone. | **PASS** — Task 5 addresses imperfect specificity/sensitivity and the need for context and tissue diagnosis. |

**Adversarial status:** R1 `ES-01` BLOCK repaired across definition, diagrams,
case, task, cheat sheet, confusions, and overview; no finding open.
**Ordinary PROOF:** PASS, 0 / 0.
**Da Vinci:** missing; no neoplastic-control or invasion-cascade invariant.
**Source custody:** partial; PROOF backfill present, Git provenance pending, external
sources incomplete.
**Tier: Silver.**

---

## `pathology/06-GENETIC-DEVELOPMENTAL-AND-METABOLIC-PATHOLOGY.md`

| Gold dimension | Score | Guide-specific evidence |
|---|---:|---|
| Landscape power | 5 | The genotype/developmental-error-to-tissue “compile” diagram connects variant class, pathway disturbance, timing, host context, and lesion. |
| Layering integrity | 5 | Disorder classes lead to mutation-to-lesion mechanisms, metabolic blocks, storage, malformations, perinatal vulnerability, and phenotype variation. |
| ASCII precision | 4 | Compile and metabolic-block diagrams are clear but necessarily dense with branching consequences. |
| Explanatory compression | 5 | The guide turns genetics into pathology through dosage, toxic gain, loss of function, substrate accumulation, deficiency, and developmental timing. |
| Decision utility | 5 | It helps choose lesion mechanisms from chromosome-scale, single-gene, metabolic, storage, and developmental patterns. |
| Confusion handling | 5 | Genotype vs phenotype, penetrance vs expressivity, malformation vs disruption/deformation, and pathology vs genomics ownership are explicit. |
| Bridge quality | 5 | Compilation, dependency graphs, and blocked-pipeline bridges map cleanly to tissue consequences. |
| Cross-reference value | 4 | Defers sequence/gene mechanics to genomics and biochemistry while returning tissue-level consequences; links to development and disease entities. |
| Voice | 5 | Third-person and educational, with no personal genetic interpretation. |
| Factual confidence | 4 | Mechanism classes are well bounded and variability is explicit; authentic source custody remains incomplete. |

**Average: 4.7/5.**

| Reader task | Pass/fail evidence |
|---|---|
| Explain multisystem chromosomal effects vs narrower single-gene effects. | **PASS** — Task 1 uses gene dosage across many loci versus pathway-focused disruption. |
| Explain variable severity for the same variant. | **PASS** — Task 2 applies penetrance, expressivity, modifiers, environment, and mosaicism. |
| Predict consequences of a metabolic block. | **PASS** — Task 3 identifies substrate accumulation, product deficiency, toxic diversion, and energy failure. |

**Adversarial status:** no unresolved guide-specific R1 finding.
**Ordinary PROOF:** PASS, 0 / 0.
**Da Vinci:** missing; no genotype-to-lesion invariant.
**Source custody:** partial; PROOF backfill present, Git provenance pending, external
sources incomplete.
**Tier: Silver.**

---

## `pathology/07-ENVIRONMENTAL-NUTRITIONAL-AND-TOXIC-INJURY.md`

| Gold dimension | Score | Guide-specific evidence |
|---|---:|---|
| Landscape power | 5 | The exposure→dose→distribution/metabolism→cellular target→lesion map unifies physical, chemical, occupational, deficiency, and overload injury. |
| Layering integrity | 5 | Physical injury leads to toxicokinetic principles, exposure patterns, deficiencies, excesses, and the unifying dose/host model. |
| ASCII precision | 4 | Exposure and dose-response diagrams carry causal structure; broad modality coverage makes labels dense. |
| Explanatory compression | 5 | “Dose makes the poison” is expanded into route, duration, metabolism, target, reserve, and susceptibility rather than used as a slogan. |
| Decision utility | 5 | The guide selects direct vs metabolite-mediated toxicity, local vs distant injury, deficiency vs excess, and acute vs cumulative exposure patterns. |
| Confusion handling | 5 | Hazard vs risk, exposure vs dose, deficiency vs starvation, and ionizing vs non-ionizing mechanisms are explicit. |
| Bridge quality | 5 | Threat modeling, ingress, transformation, and capacity/reserve bridges support the causal model. |
| Cross-reference value | 4 | Links to neoplasia, cell injury, nutrition, public health, and disease entities without duplicating exposure regulation or treatment. |
| Voice | 5 | Third-person and non-prescriptive. |
| Factual confidence | 4 | R1 repaired the non-ionizing overgeneralization by separating UV photochemistry from IR/RF thermal injury; custody remains partial. |

**Average: 4.7/5.**

| Reader task | Pass/fail evidence |
|---|---|
| Explain why dose matters even for ordinarily harmless substances. | **PASS** — Task 1 relates concentration, duration, route, reserve, and homeostatic capacity. |
| Explain injury in an organ distant from exposure. | **PASS** — Task 2 traces absorption, distribution, bioactivation, and target-organ susceptibility. |
| Reconcile radiation therapy with radiation carcinogenesis. | **PASS** — Task 5 separates controlled tissue killing from mutagenic survivor risk and distinguishes ionizing, UV, and thermal mechanisms. |

**Adversarial status:** R1 `ES-05` BLOCK repaired in the big-picture diagram,
prose, and cheat sheet; no finding open.
**Ordinary PROOF:** PASS, 0 / 0.
**Da Vinci:** missing; no exposure-to-lesion invariant.
**Source custody:** partial; PROOF backfill present, Git provenance pending, external
sources incomplete.
**Tier: Silver.**

---

## `pathology/08-LABORATORY-MEDICINE.md`

| Gold dimension | Score | Guide-specific evidence |
|---|---:|---|
| Landscape power | 5 | The result-as-manufactured-product model connects preanalytic state, measurand, procedure, calibration, uncertainty, interference, validation, and release. |
| Layering integrity | 5 | Measurand/traceability lead to error budgets, range/detection, sensitivity meanings, interference, method comparison, discipline-specific manufacture, and release controls. |
| ASCII precision | 4 | Calibration, total-error, detection-limit, comparison, and result-flow figures are precise; metrology density is high. |
| Explanatory compression | 5 | Typed-value, tolerance, error-budget, and reproducible-build bridges make laboratory metrology memorable without displacing the formalism. |
| Decision utility | 5 | The guide distinguishes measurand from procedure, analytical from clinical sensitivity, imprecision from bias, standardization from harmonization, and serial change from cross-method difference. |
| Confusion handling | 5 | The central Sn/Sp ambiguity, TEcalc vs TEa, LoB/LoD/LoQ, RCV scope, interference, and reference interval vs decision limit are explicit. |
| Bridge quality | 5 | Type systems, calibration as inverse modeling, reproducible builds, and error budgets form a coherent engineering bridge. |
| Cross-reference value | 5 | The `08`→`medicine/10`→`clinical-medicine/03` split and `08`↔`11` seam are explicit and bidirectionally useful. |
| Voice | 5 | Third-person throughout after the final measurand/procedure wording cleanup; no bench or personal-result instruction. |
| Factual confidence | 4 | Prototype R1/R2 and full R1 repaired unit matching, RCV misuse, LoB, framework scope, and measurand/procedure conflation; primary-source custody remains partial. |

**Average: 4.8/5.**

| Reader task | Pass/fail evidence |
|---|---|
| Analyze an implausible potassium result without interpreting a real patient. | **PASS** — Task 1 routes preanalytic interference, sample integrity, analyzer flags, and release controls through the total testing process. |
| Explain cross-hospital disagreement for the same analyte. | **PASS** — Task 2 separates different measurands from method bias, calibration traceability, harmonization, and uncertainty. |
| Challenge “ten times more sensitive.” | **PASS** — Task 3 forces the distinction among analytical detection capability, diagnostic sensitivity, and marketing ambiguity. |

**Adversarial status:** prototype R1/R2 passed; full R1 `ES-06` and `RE-02`
repaired; final two second-person tokens removed. No finding open.
**Ordinary PROOF:** PASS, 0 / 0.
**Da Vinci:** missing; no result-manufacture/metrology invariant.
**Source custody:** partial; PROOF backfill present, Git provenance pending, external
sources incomplete.
**Tier: Silver.**

---

## `pathology/09-ANATOMIC-PATHOLOGY-TECHNIQUE.md`

| Gold dimension | Score | Guide-specific evidence |
|---|---:|---|
| Landscape power | 5 | The slide-as-lossy-irreversible-compile diagram makes every substrate transformation and information loss visible. |
| Layering integrity | 5 | Gross sampling, fixation, processing/projection, staining, IHC, cytology, frozen section, and molecular/digital interfaces follow the substrate pipeline. |
| ASCII precision | 4 | The compile pipeline and purpose/failure/consequence diagrams are strong; technical substrate labels create some density. |
| Explanatory compression | 5 | “Purpose → failure mode → downstream consequence” compresses technique without turning the guide into a runnable SOP. |
| Decision utility | 5 | It explains what evidence a substrate can support, which artifact can invalidate it, and when a limitation belongs in the downstream interpretation. |
| Confusion handling | 5 | Sampling vs sectioning, fixation vs preservation, negative stain vs absent target, cytology architecture limits, and frozen vs permanent quality are explicit. |
| Bridge quality | 5 | Compiler, lossy transform, projection, and observability bridges are technically precise. |
| Cross-reference value | 5 | Clean substrate handoffs to `08` result generation, `10` analytical-validity/diagnosis, and `11` system governance. |
| Voice | 5 | Stage-2 confirms third-person descriptive states and zero runnable bench steps. |
| Factual confidence | 4 | R1 repaired imperative procedure creep, cytology substrate overclaim, and small-biopsy orientation absolutism; source custody remains partial. |

**Average: 4.8/5.**

| Reader task | Pass/fail evidence |
|---|---|
| Explain why a margin can be unassessable despite excellent staining. | **PASS** — Task 1 traces orientation/sampling information loss that staining cannot recover. |
| Interpret a negative IHC result on decalcified tissue as a substrate question. | **PASS** — Task 2 connects decalcification-related antigen/nucleic-acid damage, controls, and bounded interpretation. |
| Explain the architecture limit of thyroid cytology. | **PASS** — Task 4 distinguishes meaningful cell-group patterns from unavailable tissue-level capsular/vascular invasion evidence. |

**Adversarial status:** Stage-2 whole-procedure PASS; full R1 `ES-02`,
`ES-03`, and `ES-04` repaired; no finding open.
**Ordinary PROOF:** PASS, 0 / 0.
**Da Vinci:** missing; no gross-to-glass compile invariant.
**Source custody:** partial; PROOF backfill present, Git provenance pending, external
sources incomplete.
**Tier: Silver.**

---

## `pathology/10-DIAGNOSIS-PATTERN-RECOGNITION-AND-REPORTING.md`

| Gold dimension | Score | Guide-specific evidence |
|---|---:|---|
| Landscape power | 5 | The diagnosis-as-inference-pipeline figure links pattern, differential family, ancillary evidence, certainty, classification, report, delivery, and correction. |
| Layering integrity | 5 | Morphologic language and short-list construction lead to the parse matrix, evidence gates, certainty dimensions, classification axes, report interface, communication, and amendments. |
| ASCII precision | 5 | The inference pipeline, multidimensional parse matrix, evidence gates, and versioned report payload are unusually exact and mutually consistent. |
| Explanatory compression | 5 | Parser, type-checking, evidence-gate, and versioned-interface bridges compress diagnostic reasoning without pretending it is deterministic lookup. |
| Decision utility | 5 | The guide decides pattern family, ancillary-test role, certainty language, grade/stage/margin separation, report structure, escalation, and amendment type. |
| Confusion handling | 5 | Pattern vs diagnosis, analytical validity vs diagnostic evidence, Sn/Sp/LR vs PPV/posterior, grade vs stage vs margin, and addendum vs amendment are explicit. |
| Bridge quality | 5 | Compilation, parsing, schema, API contract, and versioning bridges are load-bearing and domain-faithful. |
| Cross-reference value | 5 | Strong handoffs to `09` substrate validity, `08` signal generation, `11` governance, clinical decision theory, and disease-specific classifications. |
| Voice | 5 | Third-person, calibrated, and non-diagnostic for the reader. |
| Factual confidence | 4 | Prototype R1/R2 repaired certainty, prevalence/spectrum, margin, staging, synoptic, and cytology claims; external custody remains partial. |

**Average: 4.9/5.**

| Reader task | Pass/fail evidence |
|---|---|
| Explain why granulomatous inflammation is a pattern, not a final diagnosis. | **PASS** — Task 1 moves from pattern to cause families and ancillary evidence while deferring entities. |
| Explain when a negative immunostain is uninformative. | **PASS** — Task 2 checks substrate/controls and expected performance before treating absence of signal as evidence. |
| Separate low grade from advanced stage. | **PASS** — Task 4 treats microscopic differentiation and anatomical extent as orthogonal axes. |

**Adversarial status:** prototype R1/R2 passed; full R1 `RE-02` repaired;
no finding open.
**Ordinary PROOF:** PASS, 0 / 0.
**Da Vinci:** missing; no inference-pipeline or report-payload invariant.
**Source custody:** partial; PROOF backfill present, Git provenance pending, external
sources incomplete.
**Tier: Silver.**

---

## `pathology/11-QUALITY-ERROR-AND-THE-DIAGNOSTIC-LABORATORY-AS-SYSTEM.md`

| Gold dimension | Score | Guide-specific evidence |
|---|---:|---|
| Landscape power | 5 | The process-not-result quality map connects local control, program governance, phase-indexed error, validation, change, incidents, accreditation, flow, audit, and resilience. |
| Layering integrity | 5 | The `08`↔`11` seam is established first, then QC/QA/EQA, error taxonomy, fitness governance, change/competence, incident loops, accreditation, flow, audit, and resilience. |
| ASCII precision | 4 | The layered control system, phase taxonomy, incident loop, and resilience diagrams are clear; governance breadth creates density. |
| Explanatory compression | 5 | Control-plane, observability, change-management, and resilience bridges unify laboratory quality without duplicating clinical system-safety theory. |
| Decision utility | 5 | The guide distinguishes IQC/EQA/PT, warning/rejection, correction/corrective/preventive action, validation/verification, certification/accreditation, and audit instruments. |
| Confusion handling | 5 | It explicitly rejects EQA as ground truth, `1_2s` as automatic rejection, addenda as automatic defects, accreditation as certification, and routine traceability as legal chain of custody. |
| Bridge quality | 5 | SRE/control-plane/postmortem/resilience bridges are rigorous and appropriately deferred to `clinical-medicine/11` for general safety science. |
| Cross-reference value | 5 | The `08` seam is precise; links to `09`, `10`, and clinical safety identify ownership rather than repeat content. |
| Voice | 5 | Stage-2 confirms conceptual, dated, third-person governance with no compliance how-to or forensic instruction. |
| Factual confidence | 4 | The whole-seam review repaired QC-chart semantics, CAPA, EQA/PT, accreditation, validation, amendments, audit, and resource assumptions; custody remains partial. |

**Average: 4.8/5.**

| Reader task | Pass/fail evidence |
|---|---|
| Explain how EQA can detect discordance while IQC is in control. | **PASS** — Task 2 distinguishes local stability from external comparison and the limits of each. |
| Decide whether a rising amendment rate is actionable. | **PASS** — Task 3 requires stratification into correction/retraction defects versus non-defect addenda. |
| Separate method validation, laboratory accreditation, and individual-result validity. | **PASS** — Task 4 assigns each to a different evidence/governance layer and states that none substitutes for the others. |

**Adversarial status:** Stage-2 whole-seam PASS after all recorded repairs; full
R1 residual review clean; no finding open.
**Ordinary PROOF:** PASS, 0 / 0.
**Da Vinci:** missing; no laboratory-quality-system invariant.
**Source custody:** partial; PROOF backfill present, Git provenance pending, external
sources incomplete.
**Tier: Silver.**

---

## Module-Level Summary Matrix

| Guide | Average | Minimum | Reader tasks | Adversarial status | Ordinary PROOF | Da Vinci | Source custody | Tier |
|---|---:|---:|---:|---|---|---|---|---|
| `00-OVERVIEW` | 4.7 | 4 | 3/3 pass | `RE-01` repaired | 0 errors / 0 warnings | Missing | Partial | Silver |
| `01-CELL-INJURY-ADAPTATION-AND-DEATH` | 4.7 | 4 | 3/3 pass | Final apoptosis hygiene repair; none open | 0 / 0 | Missing | Partial | Silver |
| `02-INFLAMMATION-AND-TISSUE-REPAIR` | 4.7 | 4 | 3/3 pass | None open | 0 / 0 | Missing | Partial | Silver |
| `03-HEMODYNAMIC-DISORDERS-THROMBOSIS-AND-SHOCK` | 4.7 | 4 | 3/3 pass | None open | 0 / 0 | Missing | Partial | Silver |
| `04-IMMUNOPATHOLOGY-AND-TISSUE-INJURY` | 4.7 | 4 | 3/3 pass | None open | 0 / 0 | Missing | Partial | Silver |
| `05-NEOPLASIA-CARCINOGENESIS-AND-TUMOR-BIOLOGY` | 4.7 | 4 | 3/3 pass | `ES-01` repaired | 0 / 0 | Missing | Partial | Silver |
| `06-GENETIC-DEVELOPMENTAL-AND-METABOLIC-PATHOLOGY` | 4.7 | 4 | 3/3 pass | None open | 0 / 0 | Missing | Partial | Silver |
| `07-ENVIRONMENTAL-NUTRITIONAL-AND-TOXIC-INJURY` | 4.7 | 4 | 3/3 pass | `ES-05` repaired | 0 / 0 | Missing | Partial | Silver |
| `08-LABORATORY-MEDICINE` | 4.8 | 4 | 3/3 pass | Prototype R1/R2; `ES-06`, `RE-02` repaired | 0 / 0 | Missing | Partial | Silver |
| `09-ANATOMIC-PATHOLOGY-TECHNIQUE` | 4.8 | 4 | 3/3 pass | Stage-2 PASS; `ES-02`–`04` repaired | 0 / 0 | Missing | Partial | Silver |
| `10-DIAGNOSIS-PATTERN-RECOGNITION-AND-REPORTING` | 4.9 | 4 | 3/3 pass | Prototype R1/R2; `RE-02` repaired | 0 / 0 | Missing | Partial | Silver |
| `11-QUALITY-ERROR-AND-THE-DIAGNOSTIC-LABORATORY-AS-SYSTEM` | 4.8 | 4 | 3/3 pass | Stage-2 PASS after repair | 0 / 0 | Missing | Partial | Silver |

**Module mean: 4.74/5.** All twelve guides clear the content-side scoring and
reader-task thresholds. All twelve remain **Silver** because pathology-specific Da
Vinci invariants are absent and external source custody remains partial.

## Registry Non-Insertion Decision

**No registry insertion in Pulse 05.** Strong scores do not authorize a Certified
Gold or Candidate-Hardened claim. `context/gold/REGISTRY.md` remains unchanged.

Future promotion work:

1. Add guide-specific semantic Da Vinci invariants for each load-bearing opening or
   formalism figure.
2. Complete and review authentic external/primary-source custody for load-bearing
   claims and standards.
3. Regenerate after real git history exists so the custody ledger can record actual
   provenance rather than `pending`.
4. Re-run ordinary focused PROOF and the scoped Da Vinci gate, inspect literal
   PASS/FAIL output, and repeat guide-specific adversarial/reader-task sign-off.
5. Only then consider explicit Certified Gold registry rows.

Until then, **Silver is the final tier decision for this review**. Gold, Da Vinci,
and external-source completion are optional future work, not Pulse-05 blockers.
The final reviewer returned **PASS**; Pulse 05 is **DONE**.
